BioDlink International (1875) Receives Voluntary Conditional Cash Offers from WuXi XDC (2268)

Bulletin Express

Feb 12

BioDlink International Company Limited (Stock Code: 1875) and WuXi XDC Cayman Inc. (Stock Code: 2268) have released a Composite Offer and Response Document dated 12 February 2026 regarding voluntary conditional cash offers. Citigroup Global Markets Asia Limited is acting on behalf of WuXi XDC. The document outlines terms and conditions for acquiring all issued shares of BioDlink International (excluding shares already owned or agreed to be acquired by WuXi XDC and its concert parties), as well as an offer to cancel outstanding share options.

The share offer price is set at HK$4.00 in cash per share, subject to an acceptance level that results in WuXi XDC holding at least 60% of the voting rights in BioDlink International. If fully accepted, the total consideration could reach approximately HK$3.1 billion. The transaction also includes an option offer to cancel all outstanding share options at HK$1.7665 per option, calculated as the “see-through” price.

The Composite Document provides procedures for acceptance, including completion of the relevant forms on or before 13 March 2026 (unless extended). It also states plans to maintain BioDlink International’s listing status on the Stock Exchange, subject to regulatory requirements and the necessary public float percentage. Interested parties are advised to review details in the official document for specific schedules and acceptance procedures.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1106133540"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106133540\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106133540?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 06:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106133540","market":"us","top_or_hot":-1,"title":"BioDlink International (1875) Receives Voluntary Conditional Cash Offers from WuXi XDC (2268)","media":"Bulletin Express","content":"<p>BioDlink International Company Limited (Stock Code: 1875) and WuXi XDC Cayman Inc. (Stock Code: 2268) have released a Composite Offer and Response Document dated 12 February 2026 regarding voluntary conditional cash offers. Citigroup Global Markets Asia Limited is acting on behalf of WuXi XDC. The document outlines terms and conditions for acquiring all issued shares of BioDlink International (excluding shares already owned or agreed to be acquired by WuXi XDC and its concert parties), as well as an offer to cancel outstanding share options.</p>\n<p>The share offer price is set at HK$4.00 in cash per share, subject to an acceptance level that results in WuXi XDC holding at least 60% of the voting rights in BioDlink International. If fully accepted, the total consideration could reach approximately HK$3.1 billion. The transaction also includes an option offer to cancel all outstanding share options at HK$1.7665 per option, calculated as the “see-through” price.</p>\n<p>The Composite Document provides procedures for acceptance, including completion of the relevant forms on or before 13 March 2026 (unless extended). It also states plans to maintain BioDlink International’s listing status on the Stock Exchange, subject to regulatory requirements and the necessary public float percentage. Interested parties are advised to review details in the official document for specific schedules and acceptance procedures.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioDlink International (1875) Receives Voluntary Conditional Cash Offers from WuXi XDC (2268)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioDlink International (1875) Receives Voluntary Conditional Cash Offers from WuXi XDC (2268)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-12 06:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioDlink International Company Limited (Stock Code: 1875) and WuXi XDC Cayman Inc. (Stock Code: 2268) have released a Composite Offer and Response Document dated 12 February 2026 regarding voluntary conditional cash offers. Citigroup Global Markets Asia Limited is acting on behalf of WuXi XDC. The document outlines terms and conditions for acquiring all issued shares of BioDlink International (excluding shares already owned or agreed to be acquired by WuXi XDC and its concert parties), as well as an offer to cancel outstanding share options.</p>\n<p>The share offer price is set at HK$4.00 in cash per share, subject to an acceptance level that results in WuXi XDC holding at least 60% of the voting rights in BioDlink International. If fully accepted, the total consideration could reach approximately HK$3.1 billion. The transaction also includes an option offer to cancel all outstanding share options at HK$1.7665 per option, calculated as the “see-through” price.</p>\n<p>The Composite Document provides procedures for acceptance, including completion of the relevant forms on or before 13 March 2026 (unless extended). It also states plans to maintain BioDlink International’s listing status on the Stock Exchange, subject to regulatory requirements and the necessary public float percentage. Interested parties are advised to review details in the official document for specific schedules and acceptance procedures.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01875","symbol_name":"东曜药业-B","start_time":0,"source_url":"","article_id":"1106133540","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106133540","pubTimestamp":1770849928,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"BioDlink International Company Limited (Stock Code: 1875) and WuXi XDC Cayman Inc. (Stock Code: 2268) have released a Composite Offer and Response Document dated 12 February 2026 regarding voluntary...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01875":"东曜药业-B"},"translate_title":"BioDlink International(1875)收到无锡XDC(2268)的自愿有条件现金要约","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01875":1},"content_text":"BioDlink International Company Limited (Stock Code: 1875) and WuXi XDC Cayman Inc. (Stock Code: 2268) have released a Composite Offer and Response Document dated 12 February 2026 regarding voluntary conditional cash offers. Citigroup Global Markets Asia Limited is acting on behalf of WuXi XDC. The document outlines terms and conditions for acquiring all issued shares of BioDlink International (excluding shares already owned or agreed to be acquired by WuXi XDC and its concert parties), as well as an offer to cancel outstanding share options.\nThe share offer price is set at HK$4.00 in cash per share, subject to an acceptance level that results in WuXi XDC holding at least 60% of the voting rights in BioDlink International. If fully accepted, the total consideration could reach approximately HK$3.1 billion. The transaction also includes an option offer to cancel all outstanding share options at HK$1.7665 per option, calculated as the “see-through” price.\nThe Composite Document provides procedures for acceptance, including completion of the relevant forms on or before 13 March 2026 (unless extended). It also states plans to maintain BioDlink International’s listing status on the Stock Exchange, subject to regulatory requirements and the necessary public float percentage. Interested parties are advised to review details in the official document for specific schedules and acceptance procedures.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}